Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with thalidomide and dexamethasone in relapsed or refractory multiple myeloma
2011-005121-49Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab, thalidomide, dexamethasone in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Feb 2012; status: completed.
02
Drugs
elotuzumabthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-005121-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005121-49.